Abstract
This month’s article covers 6 December 2011–5 January 2012, typically a fairly quiet period for business activity. Despite this, a number of significant announcements were made during this period. These included licensing and collaboration deals between Liquidia and PATH, Arecor and Lilly, and Arrowhead and Alnylam. Christmas presents arrived early for Endo and Grünenthal in the form of US FDA approval for their crush-resistant Opana® ER formulation and the granting of a patent covering its formulation by the US Patent and Trademark Office. Pulmatrix also had something to celebrate when on 5 January 2012, the European Patent Office approved a patent that protects the composition of matter of its lead dry powder formulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
